MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective We tested the hypothesis that the risk of intracranial hemorrhage (ICH) in patients with cardioembolic ischemic stroke who are treated with oral anticoagulants (OAs) can be predicted by evaluating surrogate markers of hemorrhagic-prone cerebral angiopathies using a baseline MRI.
Methods Patients were participants in a multicenter and prospective observational study. They were older than 64 years, had a recent cardioembolic ischemic stroke, and were new users of OAs. They underwent a baseline MRI analysis to evaluate microbleeds, white matter hyperintensities, and cortical superficial siderosis. We collected demographic variables, clinical characteristics, risk scores, and therapeutic data. The primary endpoint was ICH that occurred during follow-up. We performed bivariate and multivariate Cox regression analyses.
Results We recruited 937 patients (aged 77.6 ± 6.5 years; 47.9% were men). Microbleeds were detected in 207 patients (22.5%), moderate/severe white matter hyperintensities in 419 (45.1%), and superficial siderosis in 28 patients (3%). After a mean follow-up of 23.1 ± 6.8 months, 18 patients (1.9%) experienced an ICH. In multivariable analysis, microbleeds (hazard ratio 2.7, 95% confidence interval [CI] 1.1–7, p = 0.034) and moderate/severe white matter hyperintensities (hazard ratio 5.7, 95% CI 1.6–20, p = 0.006) were associated with ICH (C index 0.76, 95% CI 0.66–0.85). Rate of ICH was highest in patients with both microbleed and moderate/severe WMH (3.76 per 100 patient-years, 95% CI 1.62–7.4).
Conclusion Patients taking OAs who have advanced cerebral small vessel disease, evidenced by microbleeds and moderate to severe white matter hyperintensities, had an increased risk of ICH. Our results should help to determine the risk of prescribing OA for a patient with cardioembolic stroke.
ClinicalTrials.gov identifier NCT02238470.
Glossary
- AF=
- atrial fibrillation;
- CAA=
- cerebral amyloid angiopathy;
- CHA=
- cerebral hypertensive angiopathy;
- CHA2DS2-VASc=
- congestive heart failure (or left ventricular systolic dysfunction), hypertension: blood pressure consistently above 140/90 mm Hg (or treated hypertension on medication), age ≥75 years, diabetes mellitus, prior stroke or TIA or thromboembolism, vascular disease (e.g., peripheral artery disease, myocardial infarction, aortic plaque), age 65–74 years, sex category (i.e., female sex);
- CI=
- confidence interval;
- CROMIS-2=
- Clinical Relevance of Microbleeds in Stroke–2;
- cSS=
- cortical superficial siderosis;
- DOAC=
- direct oral anticoagulant;
- FLAIR=
- fluid-attenuated inversion recovery;
- GRE=
- gradient-recalled echo;
- HAS-BLED=
- hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, elderly, drugs or alcohol;
- HERO=
- Hemorrhage Predicted by Resonance in Patients Receiving Oral Anticoagulants;
- HR=
- hazard ratio;
- ICH=
- intracranial hemorrhage;
- INR=
- international normalized ratio;
- MB=
- microbleed;
- OA=
- oral anticoagulant;
- SS=
- superficial siderosis;
- SWI=
- susceptibility-weighted imaging;
- VKA=
- vitamin K antagonist;
- WMH=
- white matter hyperintensity;
- WML=
- white matter lesion
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
HERO coinvestigators are listed in appendix 2.
Editorial, page 981
- Received August 25, 2018.
- Accepted in final form January 24, 2019.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Author response: MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation
- Joan Martí-Fàbregas, Neurologist, Hospital de la Santa Creu i Sant Pau
- Luis Prats-Sánchez, Neurologist, Hospital de la Santa Creu i Sant Pau
Submitted July 01, 2019 - Reader response: MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation
- George K. Vilanilam, Research Fellow, Mayo Clinic, Florida
- Mohammed K. Badi, Research Fellow, Mayo Clinic, Florida
- Neethu Gopal, Research Fellow, Mayo Clinic, Florida
- Kaneez Zahra, Research Trainee, Mayo Clinic, Florida
Submitted May 28, 2019
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Review
Anticoagulation for atrial fibrillation after intracranial hemorrhageA systematic reviewMaximiliano A. Hawkes, Alejandro A. Rabinstein et al.Neurology: Clinical Practice, January 22, 2018 -
Articles
Rapid appearance of new cerebral microbleeds after acute ischemic strokeS. -B. Jeon, S. U. Kwon, A. -H. Cho et al.Neurology, September 16, 2009 -
Article
Detection of Cerebral Microbleeds With Venous Connection at 7-Tesla MRIJohanna Rotta, Valentina Perosa, Renat Yakupov et al.Neurology, March 02, 2021 -
Articles
Incidence of cerebral microbleedsA longitudinal study in a memory clinic populationJ.D.C. Goos, W.J.P. Henneman, J.D. Sluimer et al.Neurology, June 14, 2010